The Federal Trade Commission ordered Illumina to divest its controversial acquisition of cancer test developer Grail. The commission said the deal would stifle competition and innovation in the U.S.

Illumina said today it agreed to acquire the majority stake it does not already own in cancer blood test developer GRAIL for $8 billion in cash and stock, confirming nearly a week of speculation that ...

HackerRank for Work, a service that helps businesses send assessment tests to developer job candidates, is today launching the Test Health Dashboard, a machine learning-enhanced tool that helps ...

The new tools will help mods and let people make posts with live scoreboards, but they’ll only be available to a small number of communities to start. The new tools will help mods and let people make ...

The Federal Trade Commission (FTC) on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The ...

Self-healing tests became the QA industry's biggest bet in 2025. Vendors claim AI can fix broken automation overnight. Engineering teams are burning budgets on tools that supposedly eliminate ...